Overexpression of annexin A5 might guide the gemtuzumab ozogamicin treatment choice in patients with pediatric acute myeloid leukemia.

Nan ZhangYing ZhangPing ZhangShifeng LouYing ChenHuan LiHanqing ZengYan ShenJianchuan Deng

Published in: Therapeutic advances in medical oncology (2020)

The expression level of ANXA5 can help optimize the treatment regimen for individual patients, and patients with overexpression of ANXA5 may circumvent poor outcomes from chemotherapy combined with GO.

Keyphrases

acute myeloid leukemia
end stage renal disease
newly diagnosed
cell proliferation
poor prognosis
ejection fraction
chronic kidney disease
combination therapy
radiation therapy
patient reported outcomes
allogeneic hematopoietic stem cell transplantation